Biological treatment of severe/difficult asthma

被引：0

作者：

Lukaszyk, Mateusz ^{[1
]}

Jastrzebska, Ewelina ^{[1
]}

Zietkowski, Ziemowit ^{[2
]}

Bodzenta-Lukaszyk, Anna ^{[2
]}

机构：

[1] Uniwersytet Med Bialymstoku, Bialystok, Poland

[2] Uniwersytet Med Bialymstoku, Klin Alergol & Chorob Wewnetrznych, Ul M Sklodowskiej Curie 24, PL-15276 Bialystok, Poland

来源：

ALERGIA ASTMA IMMUNOLOGIA | 2013年 / 18卷 / 02期

关键词：

severe/difficult asthma; omalizumab; mepolizumab; lebrikizumab;

D O I：

暂无

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Asthma is a chronic inflammatory disease of the airways. Nearly 60% of asthma cases have allergic background. About 5-10% of patients treated for asthma do not respond well to standard treatment suggested by GINA 2006 guidelines. The article reviews the anti-IgE therapy for patients with severe/difficult asthma as well as points out the prospects of treatment with new biological drugs now being in 2nd and 3rd phase of clinical trials, which may play a significant role in severe asthma treatment in the near future.

引用

收藏

页码：86 / 90

页数：5

相关论文

共 36 条

[1] Monoclonal antibodies for asthma and chronic obstructive pulmonary disease [J].

Antoniu, Sabina Antonela .

EXPERT OPINION ON BIOLOGICAL THERAPY, 2013, 13 (02) :257-268

[2] Severe asthma: Advances in current management and future therapy [J].

Barnes, Peter J. .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2012, 129 (01) :48-59

[3] Omalizumab: an anti-immunoglobulin E antibody for the treatment of allergic respiratory diseases [J].

Bousquet, J. ;

Wahn, U. ;

Meltzer, E. O. ;

Fox, H. ;

Hedgecock, S. ;

Thomas, K. ;

Fowler-Taylor, A. .

EUROPEAN RESPIRATORY REVIEW, 2008, 17 (107) :1-9

[4] "Real-life" effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study [J].

Brusselle, G. ;

Michils, A. ;

Louis, R. ;

Dupont, L. ;

de Maele, B. Van ;

Delobbe, A. ;

Pilette, C. ;

Lee, C. S. ;

Gurdain, S. ;

Vancayzeele, S. ;

Lecomte, P. ;

Hermans, C. ;

MacDonald, K. ;

Song, M. ;

Abraham, I. .

RESPIRATORY MEDICINE, 2009, 103 (11) :1633-1642

[5] Omalizumab and the risk of malignancy: Results from a pooled analysis [J].

Busse, William ;

Buhl, Roland ;

Vidaurre, Carlos Fernandez ;

Blogg, Martin ;

Zhu, Jin ;

Eisner, Mark D. ;

Canvin, Janice .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2012, 129 (04) :983-U482

[6] Effect of omalizumab on symptoms of seasonal allergic rhinitis - A randomized controlled trial [J].

Casale, TB ;

Condemi, J ;

LaForce, C ;

Nayak, A ;

Rowe, M ;

Watrous, M ;

McAlary, M ;

Fowler-Taylor, A ;

Racine, M ;

Gupta, N ;

Fick, R ;

Della Cioppa, G .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (23) :2956-2967

[7] Lebrikizumab Treatment in Adults with Asthma [J].

Corren, Jonathan ;

Lemanske, Robert F., Jr. ;

Hanania, Nicola A. ;

Korenblat, Phillip E. ;

Parsey, Merdad V. ;

Arron, Joseph R. ;

Harris, Jeffrey M. ;

Scheerens, Heleen ;

Wu, Lawren C. ;

Su, Zheng ;

Mosesova, Sofia ;

Eisner, Mark D. ;

Bohen, Sean P. ;

Matthews, John G. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (12) :1088-1098

[8]

Di Domenico Monica, 2011, Inflammation & Allergy Drug Targets, V10, P2

[9] What effect does asthma treatment have on airway remodeling? Current perspectives [J].

Durrani, Sheharyar R. ;

Viswanathan, Ravi K. ;

Busse, William W. .

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2011, 128 (03) :439-448

[10] Omalizumab [J].

Easthope, S ;

Jarvis, B .

DRUGS, 2001, 61 (02) :253-260

← 1 2 3 4 →